FDA Drug recall D-0342-2023
TIROSINT - SOL (levothyroxine sodium) Oral Solution, 112 microgram/mL
- FDA Drug
- Class II
- terminated
- Published 2023-03-01
On 2023-03-01 the FDA classified a Class II recall of TIROSINT - SOL (levothyroxine sodium) Oral Solution, 112 microgram/mL by Ibsa Pharma, citing subpotent Drug.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0342-2023 |
| Classification | Class II |
| Status | terminated |
| Initiated | 2023-01-30 |
| Published | 2023-03-01 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Ibsa Pharma |
| Distribution | US |
Product
TIROSINT - SOL (levothyroxine sodium) Oral Solution, 112 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0135-5
Reason
Subpotent Drug
Identifiers
| ndc | 71858-0105-6 |
|---|---|
| ndc | 71858-0105-4 |
| ndc | 71858-0105-5 |
| ndc | 71858-0105-1 |
| ndc | 71858-0105-2 |
| ndc | 71858-0110-6 |
| ndc | 71858-0110-4 |
| ndc | 71858-0110-5 |
| ndc | 71858-0110-1 |
| ndc | 71858-0110-2 |
| ndc | 71858-0112-6 |
| ndc | 71858-0112-4 |
| ndc | 71858-0112-5 |
| ndc | 71858-0112-1 |
| ndc | 71858-0112-2 |
| ndc | 71858-0113-6 |
| ndc | 71858-0113-4 |
| ndc | 71858-0113-5 |
| ndc | 71858-0113-1 |
| ndc | 71858-0113-2 |
| ndc | 71858-0115-6 |
| ndc | 71858-0115-4 |
| ndc | 71858-0115-5 |
| ndc | 71858-0115-1 |
| ndc | 71858-0115-2 |
| ndc | 71858-0117-6 |
| ndc | 71858-0117-4 |
| ndc | 71858-0117-5 |
| ndc | 71858-0117-1 |
| ndc | 71858-0117-2 |
| ndc | 71858-0120-6 |
| ndc | 71858-0120-4 |
| ndc | 71858-0120-5 |
| ndc | 71858-0120-1 |
| ndc | 71858-0120-2 |
| ndc | 71858-0125-6 |
| ndc | 71858-0125-4 |
| ndc | 71858-0125-5 |
| ndc | 71858-0125-1 |
| ndc | 71858-0125-2 |
| ndc | 71858-0130-6 |
| ndc | 71858-0130-4 |
| ndc | 71858-0130-5 |
| ndc | 71858-0130-1 |
| ndc | 71858-0130-2 |
| ndc | 71858-0135-6 |
| ndc | 71858-0135-4 |
| ndc | 71858-0135-5 |
| ndc | 71858-0135-1 |
| ndc | 71858-0135-2 |
| ndc | 71858-0140-6 |
| ndc | 71858-0140-4 |
| ndc | 71858-0140-5 |
| ndc | 71858-0140-1 |
| ndc | 71858-0140-2 |
| ndc | 71858-0145-6 |
| ndc | 71858-0145-4 |
| ndc | 71858-0145-5 |
| ndc | 71858-0145-1 |
| ndc | 71858-0145-2 |
| ndc | 71858-0150-6 |
| ndc | 71858-0150-4 |
| ndc | 71858-0150-5 |
| ndc | 71858-0150-1 |
| ndc | 71858-0150-2 |
| ndc | 71858-0155-6 |
| ndc | 71858-0155-4 |
| ndc | 71858-0155-5 |
| ndc | 71858-0155-1 |
| ndc | 71858-0155-2 |
| ndc | 71858-0160-6 |
| ndc | 71858-0160-4 |
| ndc | 71858-0160-5 |
| ndc | 71858-0160-1 |
| ndc | 71858-0160-2 |
| code_info | Lot #: 220414, Exp. 10/2023; 220852, Exp. 02/2024; 220970, Exp. 03/2024. |
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0342-2023%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.